Detrimental effect of apoptosis of lymphocytes at an early time point of experimental abdominal sepsis

BMC Infectious Diseases

Evangelos J Giamarellos-Bourboulis¹  Konstantinos Atmatzidis²  Anastasia Antonopoulou¹  Athina Savva¹  Aikaterini Pistiki¹  Konstantinos Louis¹  Antigone Kotsaki¹  Grigorios Chatzimavroudis²  Ioannis M Koutelidakis²  Stefanos Atmatzidis² 

[1] 4th Department of Internal Medicine, University of Athens, Medical School, Athens, Greece;2nd Department of Surgery, University of Thessaloniki, Medical School, Thessaloniki, Greece

关键词: antimicrobials;    lymphocytes;    survival;    abdominal sepsis;    apoptosis;   

Others  :  1175528
DOI  :  10.1186/1471-2334-11-321

 received in 2011-06-30, accepted in 2011-11-20,  发布年份 2011

【 摘 要 】

Background

Apoptosis of lymphocytes is considered a late sequelum in the sepsis cascade. The role of apoptosis of lymphocytes as a driver of final outcome was investigated.

Methods

Abdominal sepsis was induced after cecal ligation and puncture (CLP) in 31 rabbits. Blood was sampled at serial time intervals and peripheral blood mononuclear cells (PBMCs) were isolated. Apoptosis of lymphocytes and monocytes was measured through flow cytometric analysis. PBMCs were stimulated with LPS and Pam3Cys for the release of tumor necrosis factor-alpha (TNFα). Tissue bacterial growth was quantitatively measured. In a second set of experiments, CLP was performed in another 40 rabbits; 20 received single intravenous infusions of ciprofloxacin and of metronidazole 4 hours after surgery.

Results

Animals were divided into two groups based on the percentage of lymphocyte apoptosis at 4 hours after surgery; less than or equal to 32% and more than 32%. Survival of the former was shorter than the latter (p: 0.017). Tissue growth was similar between groups. Apoptosis of lymphocytes and of monocytes was lower in the former group over follow-up. Release of ΤNFα did not differ. The above findings on survival were repeated in the second set of experiments. Administration of antimicrobials prolonged survival of the former group (p: 0.039) but not of the latter group (pNS).

Conclusions

Lymphocyte apoptosis at an early time point of experimental peritonitis is a major driver for death. A lower percentage of apoptosis leads earlier to death. Antimicrobials were beneficial even at that disease state.

【 授权许可】

   
2011 Atmatzidis et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Hodgin KE, Moss M: The epidemiology of sepsis. Curr Pharm Des 2008, 14:1833-1839.
• [2]Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D: Sepsis in European intensive care units. results of the SOAP study. Crit Care Med 2006, 34:344-353.
• [3]Rittisch D, Flierl MA, Ward PA: Harmful molecular mechanisms in sepsis. Nat Immunol 2008, 8:776-786.
• [4]Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE: Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005, 174:5110-5118.
• [5]Gogos C, Kotsaki A, Pelekanou A, Giannikopoulos G, Vaki I, Maravitsa P, Adamis S, Alexiou Z, Andrianopoulos G, Antonopoulou A, Athanassia S, Baziaka F, Charalambous A, Christodoulou S, Dimopoulou I, Floros I, Giannitsioti E, Gkanas P, Ioakeimidou A, Kanellakopoulou K, Karabela N, Karagianni V, Katsarolis I, Kontopithari G, Kopterides P, Koutelidakis I, Koutoukas P, Kranidioti H, Lignos M, Louis K, et al.: Early alterations of the innate and adaptive immune statuses is sepsis according to the type of underlying infection. Crit Care 2010, 14:R96. BioMed Central Full Text
• [6]Dyson A, Singer M: Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 2009, 37(Suppl):S30-S37.
• [7]Rittisch D, Huber-Lang MS, Flierl MA, Ward PA: Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 2009, 4:31-36.
• [8]Launay E, Joram N, Jacqueline C, Miegeville AF, Caillon J, Potel G, Roze JC, Gras-Le Guen C: Efficacy of ciprofloxacin in an experimental model of Escherichia coli chorioamnionitis in rabbits. Antimicrob Agents Chemother 2009, 53:1624-1627.
• [9]Mahfouz NM, Hassan MA: Synthesis, chemical and enzymatic hydrolysis, and bioavailability evaluation in rabbits of metronidazole amino acid ester prodrugs with enhanced water solubility. J Pharm Pharmacol 2001, 53:841-848.
• [10]Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, Sabracos L, Koussoulas V, Mouktaroudi M, Perrea D, Karayannacos P, Giamarellou H: Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004, 48:93-99.
• [11]Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, Baziaka F, Antonopoulou A, Adamis T, Sabracos L, Giamarellou H: Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2006, 57:937-944.
• [12]Pierrakos C, Vincent JL: Sepsis biomarkers: a review. Crit Care 2010, 14:R15. BioMed Central Full Text
• [13]Van Till JWO, van Veen SQ, van Rulen O, Lamme B, Gouma DJ, Boermeester MA: The innate immune response to secondary peritonitis. Shock 2007, 28:504-517.
• [14]Pieracci FM, Baria PS: Intra-abdominal infections. Curr Opin Crit Care 2007, 13:440-449.
• [15]de Ruiter J, Weel J, Manusama E, Kingma WP, van der Voort PHJ: The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection 2009, 37:522-527.
• [16]Weixelbaumer KM, Raeven P, Redl H, van Griensven M, Bahrami S, Osuchowski MF: Repetitive low-volume blood sampling method as a feasible monitoring tool in a mouse model of sepsis. Shock 2010, 34:420-426.
• [17]Hattori Y, Takano KI, Teramea H, Yamamoto S, Yokoo H, Matsuda N: Insights into sepsis therapeutic design based on the apoptotic death pathway. J Pharmacol Sci 2010, 114:354-365.
• [18]Hotckiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6:813-822.
• [19]Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS: Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 2010, 88:233-240.
• [20]Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS: Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J Leukoc Biol 2009, 86:219-227.
• [21]Kasten KR, Tschöp J, Adediran SG, Hindleman DA, Caldwell CC: T cells are potent early mediators of the host response to sepsis. Shock 2010, 34:327-336.
• [22]Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008, 34:17-60.
• [23]Vaki I, Kranidioti H, Karagianni V, Spyridaki A, Kotsaki A, Routsi C, Giamarellos-Bourboulis EJ: An early circulating factor in severe sepsis modulates apoptosis of lymphocytes and monocytes. J Leukoc Biol 2011, 89:343-349.